NCT02425735View on ClinicalTrials.gov

Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Liver Cancer
Interventions
BIOLOGICAL

DC-CIK cells

DC-CIK cells will be used against tumor cells.

BIOLOGICAL

γδ T cells

γδ T cells will be used against breast tumor.

BIOLOGICAL

γδ T/DC-CIK cells

γδ T/DC-CIK cells will be used against breast tumor.

Trial Locations (1)

510000

Biological treatment center in Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Jinan University Guangzhou

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02425735 - Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer | Biotech Hunter | Biotech Hunter